drugset / Trial / NCT01001832

Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients

NCT01001832

Phase 2/3 Completed 118 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy, pharmacokinetics, safety, and immunogenicity of abatacept after subcutaneous and intravenous administration in Japanese participants with active rheumatoid arthritis and inadequate response to methotrexate.

Timeline

Start
2009-12
Primary completion
2011-02
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abatacept Other / unclassified 125 mg Intravenous

Indications